{"id":4424,"date":"2019-03-26T06:39:54","date_gmt":"2019-03-26T06:39:54","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4424"},"modified":"2019-03-26T06:39:54","modified_gmt":"2019-03-26T06:39:54","slug":"%e5%81%9c%e7%94%a8%e7%bb%b4%e8%8e%ab%e6%8b%89%e9%9d%9e%e5%b0%bc%ef%bc%88braf%e6%8a%91%e5%88%b6%e5%89%82%ef%bc%89%e5%90%8e%e5%9f%83%e5%b0%94%e5%be%b7%e6%b5%b7%e5%a7%86-%e5%88%87%e6%96%af%e7%89%b9","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/zh\/study_trials\/long-term-outcome-after-vemurafenib-braf-inhibitors-interruption-in-erdheim-chester-disease-love\/","title":{"rendered":"\u57c3\u5c14\u5fb7\u6d77\u59c6-\u5207\u65af\u7279\u75c5\u60a3\u8005\u505c\u7528\u7ef4\u7a46\u62c9\u975e\u5c3c\/BRAF\u6291\u5236\u5242\u540e\u7684\u957f\u671f\u9884\u540e\uff08LOVE\u7814\u7a76\uff09"},"content":{"rendered":"<p><strong>\u7814\u7a76\u76ee\u7684\uff1a<\/strong> \u63a5\u53d7\u7ef4\u7a46\u62c9\u975e\u5c3c\u6cbb\u7597\u7684ECD\u60a3\u8005\u75c5\u60c5\u4f3c\u4e4e\u4fdd\u6301\u7a33\u5b9a\u3002\u672c\u7814\u7a76\u8bc4\u4f30\u4e86\u6682\u505c\u6cbb\u7597\u7684\u53ef\u80fd\u6027\u3002\u6700\u8fd1\uff0c\u5df2\u6709\u7814\u7a76\u63d0\u51fa\u5c06\u8fbe\u5e03\u62c9\u975e\u5c3c\u7b49\u5176\u4ed6BRAF\u6291\u5236\u5242\u7528\u4e8e\u6cbb\u7597BRAF\u7a81\u53d8\u578b\u7ec4\u7ec7\u7ec6\u80de\u589e\u751f\u75c7\u3002\u5176\u4ed6BRAF\u6291\u5236\u5242\u7684\u6682\u505c\u6cbb\u7597\u65b9\u6848\u4e5f\u5e94\u8fdb\u884c\u524d\u77bb\u6027\u8bc4\u4f30\u3002.<\/p>\n<p><strong>\u9879\u76ee\u8d1f\u8d23\u4eba\uff1a<\/strong> \u6731\u5229\u5b89\u00b7\u54c8\u7f57\u4ec0\uff08Julien Haroche\uff09\uff0c\u533b\u5b66\u535a\u58eb\u3001\u54f2\u5b66\u535a\u58eb\uff0c\u6cd5\u56fd\u5df4\u9ece\u76ae\u8482\u8036-\u8428\u5c14\u4f69\u7279\u91cc\u8036\u533b\u9662<\/p>\n<p><strong>\u8054\u7cfb\u65b9\u5f0f\uff1a<\/strong> \u7535\u8bdd\uff1a+33 1 42 17 80 37 \u7535\u5b50\u90ae\u4ef6\uff1ajulien.haroche@psl.aphp.fr<\/p>\n<p><strong>\u8981\u6c42\u60a3\u8005\u53c2\u4e0e\uff1a<\/strong> \u6b22\u8fce\u60a3\u8005\u548c\u4e3b\u6cbb\u533b\u751f\u8054\u7cfb\u6731\u5229\u5b89\u00b7\u54c8\u7f57\u4ec0\u6559\u6388\u4ee5\u83b7\u53d6\u66f4\u591a\u4fe1\u606f\u3002.<\/p>\n<p><strong>ClinicalTrials.gov \u6807\u8bc6\u7b26\uff1a<\/strong> NCT02089724<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: ECD patients with vemurafenib treatment seem to have a stable disease.&nbsp; This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[33],"class_list":["post-4424","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-observational"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/study_trials\/4424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/media?parent=4424"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/zh\/wp-json\/wp\/v2\/study_trials_cat?post=4424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}